Monday, April 8, 2024

AltPep Study Published in Nature Journal, Scientific Reports, Further Affirms Potential of Blood Test to Detect Alzheimer's Disease

›
April 05, 2024 - AltPep Corporation  , a privately held biotechnology company dedicated to early disease-modifying treatments and detection...
Monday, February 12, 2024

AlzeCure gets Late Breaking abstract of new preclinical data with ACD856 accepted at AD/PD 2024 conference

›
February 6, 2024 - AlzeCure Pharma AB (publ) (FN STO: ALZCUR) , a pharmaceutical company that develops candidate drugs for CNS diseases, fo...
Tuesday, January 30, 2024

INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program

›
The Phase II clinical trial in patients with Alzheimer’s disease with neuroinflammation is on track to complete enrollment mid-2024 with top...
Tuesday, January 23, 2024

IGC Pharma Activates ClinCloud, One Of 12 Sites In Ongoing Phase 2b Alzheimer’s Trial

›
  POTOMAC, Md., January 17, 2024 – IGC Pharma, Inc (NYSE American: IGC) (“IGC” or the “Company”) , announced that ClinCloud, a clinical re...
Monday, January 15, 2024

Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease

›
Topline data from LIFT-AD on track for second half of 2024 Previously reported independent, unblinded interim analysis supports trial contin...
Thursday, January 4, 2024

Fujirebio expands its Alzheimer’s disease test menu with the much awaited and fully automated Lumipulse® G pTau 217 Plasma assay for Research Use Only (RUO)

›
Gent, Belgium, Malvern PA, United States, and Tokyo, Japan, December 22nd, 2023 – H.U. Group Holdings Inc. and its wholly-owned subsidiary ...
Wednesday, December 20, 2023

LEQEMBI® to be launched in Japan for Alzheimer’s disease on December 20

›
Stockholm, Sweden, December 13, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai  announced that LEQEMBI (lecanemab) ...
Wednesday, November 8, 2023

JAMA Neurology Publishes Complete Results of Positive Phase 3 Study of REXULTI® (brexpiprazole) for Agitation Associated with Dementia Due to Alzheimer’s Disease

›
JAMA Neurology Publishes Complete Results of Positive Phase 3 Study of REXULTI® (brexpiprazole) for Agitation Associated with Dementia Due t...